{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:07:09Z","timestamp":1790222829397,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.atherosclerosis.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T06:24:57Z","timestamp":1489127097000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia"],"prefix":"10.1016","volume":"261","author":[{"given":"Tamio","family":"Teramoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Ikewaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kakikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Numaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Blaustein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.03.009_bib1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/CIRCOUTCOMES.111.000014","article-title":"Journey through cholesteryl ester transfer protein inhibition: from Bench to Bedside","volume":"6","author":"Karalis","year":"2013","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2017.03.009_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2017.03.009_bib3","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2017.03.009_bib4","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.03.009_bib5","series-title":"ACCELERATE ACC Abstract","author":"Evacetrapib Fails to Reduce Major Adverse Cardiovascular Events","year":"2016"},{"issue":"9992","key":"10.1016\/j.atherosclerosis.2017.03.009_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"issue":"9983","key":"10.1016\/j.atherosclerosis.2017.03.009_bib7","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2017.03.009_bib8","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.03.009_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.amjcard.2016.10.032","article-title":"Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol","volume":"119","author":"Ballantyne","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.03.009_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacl.2014.10.005","article-title":"Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial","volume":"9","author":"Brinton","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2017.03.009_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosis.2016.03.017","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia","volume":"249","author":"Arai","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9983","key":"10.1016\/j.atherosclerosis.2017.03.009_bib12","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.03.009_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2013.05.012","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia","volume":"230","author":"Teramoto","year":"2013","journal-title":"Atherosclerosis"},{"issue":"9603","key":"10.1016\/j.atherosclerosis.2017.03.009_bib14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.03.009_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.03.009_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1074248414529621","article-title":"Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study","volume":"19","author":"Gotto","year":"2014","journal-title":"J.\u00a0Cardiovasc Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.03.009_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib","volume":"54","author":"Davidson","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.03.009_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","article-title":"Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease","volume":"113","author":"Gotto","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.03.009_bib19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ahj.2011.07.010","article-title":"Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia","volume":"162","author":"Dansky","year":"2011","journal-title":"Am. Heart J."},{"issue":"supp 1","key":"10.1016\/j.atherosclerosis.2017.03.009_bib20","article-title":"Observed long plasma terminal half-life of anacetrapib is associated with adipose deposition: plasma and adipose pharmacokinetics in mice and humans","volume":"97","author":"Gutstein","year":"2015","journal-title":"Clin Pharm Ther"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2017.03.009_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-016-0622-1","article-title":"Emerging therapeutic options for lowering of lipoprotein(a): implications for prevention of cardiovascular disease","volume":"18","author":"Boffa","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2017.03.009_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","article-title":"Apolipoprotein E as a therapeutic target in Alzheimer's disease: a review of basic research and clinical evidence","volume":"30","author":"Yamazaki","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.03.009_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am. Heart J."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017301004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017301004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T17:29:30Z","timestamp":1535995770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017301004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":23,"alternative-id":["S0021915017301004"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. and Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki, Hidenori Arai. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}